Does the media favor MYGN or TSHA?

In the previous week, Myriad Genetics and Myriad Genetics both had 3 articles in the media. Myriad Genetics' average media sentiment score of 0.61 beat Taysha Gene Therapies' score of 0.55 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MYGN or NTLA?

In the previous week, Myriad Genetics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Myriad Genetics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.84 beat Myriad Genetics' score of 0.61 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor IMCR or MYGN?

In the previous week, Myriad Genetics had 1 more articles in the media than Immunocore. MarketBeat recorded 3 mentions for Myriad Genetics and 2 mentions for Immunocore. Myriad Genetics' average media sentiment score of 0.61 beat Immunocore's score of 0.20 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SNDX or MYGN?

In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Myriad Genetics. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 3 mentions for Myriad Genetics. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat Myriad Genetics' score of 0.61 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INBX or MYGN?

In the previous week, Inhibrx Biosciences had 8 more articles in the media than Myriad Genetics. MarketBeat recorded 11 mentions for Inhibrx Biosciences and 3 mentions for Myriad Genetics. Inhibrx Biosciences' average media sentiment score of 0.98 beat Myriad Genetics' score of 0.61 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Myriad Genetics (MYGN) Competitors

$4.54 +0.48 (+11.82%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.49 -0.05 (-1.15%)

As of 10/2/2026 07:59 PM Eastern

Compare

MYGN vs. TSHA, NTLA, IMCR, SNDX, and INBX

Should you buy Myriad Genetics stock or one of its competitors? Myriad Genetics's main competitors and comparable companies include Taysha Gene Therapies (TSHA), Intellia Therapeutics (NTLA), Immunocore (IMCR), Syndax Pharmaceuticals (SNDX), and Inhibrx Biosciences (INBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Myriad Genetics compare to Taysha Gene Therapies?

Myriad Genetics (NASDAQ:MYGN) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Myriad Genetics presently has a consensus target price of $3.93, suggesting a potential downside of 13.36%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 175.79%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Myriad Genetics and Myriad Genetics both had 3 articles in the media. Myriad Genetics' average media sentiment score of 0.61 beat Taysha Gene Therapies' score of 0.55 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has lower revenue, but higher earnings than Myriad Genetics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.53	-$365.90M	-$1.19	N/A
Taysha Gene Therapies	$9.77M	154.41	-$109M	-$0.42	N/A

Myriad Genetics has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Taysha Gene Therapies has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Taysha Gene Therapies beats Myriad Genetics on 9 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Intellia Therapeutics?

Myriad Genetics (NASDAQ:MYGN) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

In the previous week, Myriad Genetics had 1 more articles in the media than Intellia Therapeutics. MarketBeat recorded 3 mentions for Myriad Genetics and 2 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.84 beat Myriad Genetics' score of 0.61 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 1.9% of Myriad Genetics shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Myriad Genetics has higher revenue and earnings than Intellia Therapeutics. Myriad Genetics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.53	-$365.90M	-$1.19	N/A
Intellia Therapeutics	$59.51M	28.87	-$412.69M	-$3.36	N/A

Myriad Genetics has a net margin of -13.96% compared to Intellia Therapeutics' net margin of -672.16%. Myriad Genetics' return on equity of -16.09% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Myriad Genetics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Myriad Genetics currently has a consensus price target of $3.93, suggesting a potential downside of 13.36%. Intellia Therapeutics has a consensus price target of $20.98, suggesting a potential upside of 71.11%. Given Intellia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Intellia Therapeutics beats Myriad Genetics on 9 of the 17 factors compared between the two stocks.

How does Myriad Genetics compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Immunocore has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunocore has a net margin of -4.20% compared to Myriad Genetics' net margin of -13.96%. Immunocore's return on equity of -4.54% beat Myriad Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Immunocore has higher earnings, but lower revenue than Myriad Genetics. Immunocore is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.82	-$35.51M	-$0.37	N/A
Myriad Genetics	$824.50M	0.53	-$365.90M	-$1.19	N/A

Immunocore currently has a consensus price target of $56.38, indicating a potential upside of 89.75%. Myriad Genetics has a consensus price target of $3.93, indicating a potential downside of 13.36%. Given Immunocore's stronger consensus rating and higher possible upside, research analysts clearly believe Immunocore is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Myriad Genetics had 1 more articles in the media than Immunocore. MarketBeat recorded 3 mentions for Myriad Genetics and 2 mentions for Immunocore. Myriad Genetics' average media sentiment score of 0.61 beat Immunocore's score of 0.20 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunocore beats Myriad Genetics on 11 of the 17 factors compared between the two stocks.

How does Myriad Genetics compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Syndax Pharmaceuticals has higher earnings, but lower revenue than Myriad Genetics. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	9.05	-$285.42M	-$2.51	N/A
Myriad Genetics	$824.50M	0.53	-$365.90M	-$1.19	N/A

In the previous week, Syndax Pharmaceuticals had 3 more articles in the media than Myriad Genetics. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 3 mentions for Myriad Genetics. Syndax Pharmaceuticals' average media sentiment score of 0.74 beat Myriad Genetics' score of 0.61 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Myriad Genetics shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Syndax Pharmaceuticals currently has a consensus price target of $41.80, indicating a potential upside of 137.50%. Myriad Genetics has a consensus price target of $3.93, indicating a potential downside of 13.36%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Syndax Pharmaceuticals is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Syndax Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Myriad Genetics has a net margin of -13.96% compared to Syndax Pharmaceuticals' net margin of -87.52%. Myriad Genetics' return on equity of -16.09% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Summary

Syndax Pharmaceuticals and Myriad Genetics tied by winning 8 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

In the previous week, Inhibrx Biosciences had 8 more articles in the media than Myriad Genetics. MarketBeat recorded 11 mentions for Inhibrx Biosciences and 3 mentions for Myriad Genetics. Inhibrx Biosciences' average media sentiment score of 0.98 beat Myriad Genetics' score of 0.61 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has higher earnings, but lower revenue than Myriad Genetics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,098.23	-$140.05M	-$8.88	N/A
Myriad Genetics	$824.50M	0.53	-$365.90M	-$1.19	N/A

Inhibrx Biosciences currently has a consensus target price of $197.50, indicating a potential upside of 103.63%. Myriad Genetics has a consensus target price of $3.93, indicating a potential downside of 13.36%. Given Inhibrx Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Inhibrx Biosciences is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Inhibrx Biosciences has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Inhibrx Biosciences has a beta of 3.81, meaning that its stock price is 281% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

Summary

Inhibrx Biosciences beats Myriad Genetics on 11 of the 17 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYGN vs. The Competition

Export

Metric	Myriad Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$388.34M	$3.87B	$7.14B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	16.77%
P/E Ratio	-3.82	12.93	273.77	26.04
Price / Sales	0.53	1,331.86	622.72	93.41
Price / Cash	1.08	122.60	77.60	51.75
Price / Book	1.15	16.63	10.92	6.30
Net Income	-$365.90M	-$22.67M	$3.50B	$361.43M
7 Day Performance	8.87%	-3.10%	-2.07%	-1.67%
1 Month Performance	40.56%	-10.70%	-6.21%	-4.51%
1 Year Performance	-43.67%	19.46%	7.45%	2.03%

Myriad Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYGN Myriad Genetics	1.0764 of 5 stars	$4.54 +11.8%	$3.93 -13.4%	-39.9%	$388.34M	$824.50M	N/A	2,700	Analyst Forecast Gap Up
TSHA Taysha Gene Therapies	2.56 of 5 stars	$4.91 -1.6%	$12.77 +160.0%	-5.1%	$1.61B	$9.77M	N/A	99	News Coverage Positive News
NTLA Intellia Therapeutics	2.8518 of 5 stars	$11.46 +0.4%	$20.98 +83.1%	-40.0%	$1.60B	$67.67M	N/A	377	Gap Up
IMCR Immunocore	3.4081 of 5 stars	$30.60 -0.1%	$56.38 +84.2%	-15.8%	$1.59B	$400.02M	N/A	524	News Coverage
SNDX Syndax Pharmaceuticals	2.9937 of 5 stars	$17.86 flat	$42.30 +136.8%	+14.0%	$1.58B	$172.35M	N/A	298	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYGN) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Competitors

MYGN vs. TSHA, NTLA, IMCR, SNDX, and INBX

How does Myriad Genetics compare to Taysha Gene Therapies?

Summary

How does Myriad Genetics compare to Intellia Therapeutics?

Summary

How does Myriad Genetics compare to Immunocore?

Summary

How does Myriad Genetics compare to Syndax Pharmaceuticals?

Summary

How does Myriad Genetics compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Competitors

MYGN vs. TSHA, NTLA, IMCR, SNDX, and INBX

How does Myriad Genetics compare to Taysha Gene Therapies?

Do analysts prefer MYGN or TSHA?

Does the media favor MYGN or TSHA?

Which has preferable valuation and earnings, MYGN or TSHA?

Which has more volatility & risk, MYGN or TSHA?

Is MYGN or TSHA more profitable?

Do institutionals & insiders hold more shares of MYGN or TSHA?

Summary

How does Myriad Genetics compare to Intellia Therapeutics?

Does the media prefer MYGN or NTLA?

Do insiders & institutionals hold more shares of MYGN or NTLA?

Which has preferable earnings and valuation, MYGN or NTLA?

Is MYGN or NTLA more profitable?

Which has more risk & volatility, MYGN or NTLA?

Do analysts recommend MYGN or NTLA?

Summary

How does Myriad Genetics compare to Immunocore?

Which has more risk and volatility, IMCR or MYGN?

Do insiders & institutionals have more ownership in IMCR or MYGN?

Is IMCR or MYGN more profitable?

Which has higher valuation & earnings, IMCR or MYGN?

Do analysts prefer IMCR or MYGN?

Does the media favor IMCR or MYGN?

Summary

How does Myriad Genetics compare to Syndax Pharmaceuticals?

Which has preferable earnings & valuation, SNDX or MYGN?

Does the media favor SNDX or MYGN?

Do insiders and institutionals believe in SNDX or MYGN?

Do analysts recommend SNDX or MYGN?

Which has more volatility & risk, SNDX or MYGN?

Is SNDX or MYGN more profitable?

Summary

How does Myriad Genetics compare to Inhibrx Biosciences?

Does the media favor INBX or MYGN?

Which has higher earnings & valuation, INBX or MYGN?

Do analysts prefer INBX or MYGN?

Do institutionals & insiders believe in INBX or MYGN?

Is INBX or MYGN more profitable?

Which has more volatility & risk, INBX or MYGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools